Wetherby Asset Management Inc buys $4,739,985 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Wetherby Asset Management Inc scooped up 2,094 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 10, 2016. The investment management firm now holds a total of 87,973 shares of Merck & Co. which is valued at $4,739,985.Merck & Co. makes up approximately 1.13% of Wetherby Asset Management Inc’s portfolio.

Other Hedge Funds, Including , Samsung Asset Management (new York) reduced its stake in MRK by selling 57,620 shares or 33.74% in the most recent quarter. The Hedge Fund company now holds 113,150 shares of MRK which is valued at $6,096,522. Merck & Co. makes up approx 2.80% of Samsung Asset Management (new York)’s portfolio.Evanson Asset Management boosted its stake in MRK in the latest quarter, The investment management firm added 26 additional shares and now holds a total of 5,586 shares of Merck & Co. which is valued at $300,974. Merck & Co. makes up approx 0.10% of Evanson Asset Management’s portfolio.Ifc Holdings Incorporatedfl boosted its stake in MRK in the latest quarter, The investment management firm added 581 additional shares and now holds a total of 10,900 shares of Merck & Co. which is valued at $584,240. Merck & Co. makes up approx 0.07% of Ifc Holdings Incorporatedfl’s portfolio.United Bank boosted its stake in MRK in the latest quarter, The investment management firm added 2,562 additional shares and now holds a total of 81,344 shares of Merck & Co. which is valued at $4,460,905. Merck & Co. makes up approx 2.01% of United Bank’s portfolio.Private Wealth Partners boosted its stake in MRK in the latest quarter, The investment management firm added 1,741 additional shares and now holds a total of 213,689 shares of Merck & Co. which is valued at $11,718,705. Merck & Co. makes up approx 2.80% of Private Wealth Partners’s portfolio.

Merck & Co. opened for trading at $53.77 and hit $54.77 on the upside on Monday, eventually ending the session at $54.65, with a gain of 1.43% or 0.77 points. The heightened volatility saw the trading volume jump to 66,49,085 shares. Company has a market cap of $151,273 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.